Mekinist (trametinib) is a small molecule pharmaceutical. Trametinib was first approved as Mekinist on 2013-05-29. It is used to treat melanoma and non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat melanoma. The pharmaceutical is active against dual specificity mitogen-activated protein kinase kinase 1 and dual specificity mitogen-activated protein kinase kinase 2. In addition, it is known to target serine/threonine-protein kinase B-raf. Mekinist's patents are valid until 2033-08-30 (FDA).
|Indication||melanoma, non-small-cell lung carcinoma|
|Drug Class||Tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors|